Prime Medicine, Inc. (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.
Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases. The company is advancing several preclinical and clinical candidates designed to correct mutations in genes associated with inherited diseases, as well as to modulate immune cell function for the treatment of cancer and chronic inflammatory conditions. Through strategic collaborations and internal discovery programs, Prime Medicine seeks to establish a diverse pipeline of genome-editing therapies with potential for durable clinical benefits.
Founded in 2021 as a spin-out from leading academic laboratories at the Broad Institute of MIT and Harvard, Prime Medicine is headquartered in Cambridge, Massachusetts. Since inception, the company has assembled a team of experts in molecular biology, delivery science, and translational medicine, and has secured substantial venture capital backing to propel its platform toward clinical milestones. By leveraging its scientific heritage and industry partnerships, Prime Medicine is committed to transforming the treatment landscape for patients with serious genetic and immune-mediated diseases.
AI Generated. May Contain Errors.
Free PRME Stock Alerts